Analysts forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will announce $7.75 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Inovio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $12.99 million. Inovio Pharmaceuticals reported sales of $8.51 million during the same quarter last year, which indicates a negative year over year growth rate of 8.9%. The firm is expected to report its next earnings results on Wednesday, March 21st.
On average, analysts expect that Inovio Pharmaceuticals will report full-year sales of $7.75 million for the current financial year, with estimates ranging from $35.90 million to $46.42 million. For the next financial year, analysts forecast that the business will report sales of $17.76 million per share, with estimates ranging from $10.00 million to $22.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The company had revenue of $2.60 million for the quarter, compared to analyst estimates of $10.27 million. During the same period last year, the company posted ($0.28) EPS. The business’s revenue for the quarter was down 79.2% on a year-over-year basis.
INO has been the subject of several research analyst reports. reaffirmed a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Royal Bank Of Canada initiated coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target for the company. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. Inovio Pharmaceuticals has a consensus rating of “Hold” and an average price target of $19.16.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/15/inovio-pharmaceuticals-inc-ino-expected-to-announce-quarterly-sales-of-7-75-million.html.
Several hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. purchased a new position in shares of Inovio Pharmaceuticals in the third quarter valued at $892,000. Allianz Asset Management GmbH boosted its stake in shares of Inovio Pharmaceuticals by 12.4% in the third quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 24,652 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Inovio Pharmaceuticals in the third quarter valued at $117,000. OxFORD Asset Management LLP boosted its stake in shares of Inovio Pharmaceuticals by 410.3% in the third quarter. OxFORD Asset Management LLP now owns 126,404 shares of the biopharmaceutical company’s stock valued at $799,000 after purchasing an additional 101,633 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Inovio Pharmaceuticals by 16.1% in the third quarter. Wells Fargo & Company MN now owns 103,680 shares of the biopharmaceutical company’s stock valued at $657,000 after purchasing an additional 14,342 shares during the period. Institutional investors and hedge funds own 24.98% of the company’s stock.
Inovio Pharmaceuticals (NASDAQ:INO) opened at $4.31 on Wednesday. Inovio Pharmaceuticals has a 52-week low of $4.20 and a 52-week high of $9.86.
The firm also recently disclosed a monthly dividend, which was paid on Monday, October 16th. Stockholders of record on Friday, September 29th were given a $0.069 dividend. This represents a $0.83 annualized dividend and a dividend yield of 19.21%. The ex-dividend date of this dividend was Thursday, September 28th.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.